医学
奥马佐单抗
银屑病
免疫学
皮肤病科
单克隆
单克隆抗体
免疫球蛋白E
抗体
作者
Laura Diluvio,Chiara Pensa,Arianna Piccolo,Caterina Lanna,Luca Bianchi,Elena Campione
摘要
In Western countries, the number of individuals suffering from an autoimmune condition is constantly growing and often patients suffering from autoimmune disease are susceptible to developing a second autoimmune disorder. We report a case of an adult female patient affected by psoriasis vulgaris and treated with tildrakizumab, a humanized monoclonal antibody targeting interleukin-23, who later developed chronic spontaneous urticaria and started omalizumab, a humanized antibody to IgE, showing a favorable outcome. We speculate that the two combined therapies have restored the cytokine balance bringing it toward tolerance and remission of the two pathologies. It is conceivable that tildrakizumab may have a synergic action with omalizumab in the treatment of urticaria in patients affected by both psoriasis and urticaria. Our case and the study of the mechanisms of action of the two drugs suggest how the two therapies can act with an interlocking mechanism in achieving the final therapeutic effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI